Easing medical costs a positive for health insurers, but real test lies ahead, analysts say

• The S&P managed care index has fallen over 12% since July 2023 due to elevated healthcare utilization in Medicare plans and changes to Medicaid enrollment that brought in sicker, costlier members
• Major insurers including UnitedHealth, Cigna, Humana, Elevance Health, and Centene beat Q1 expectations in their best performance since the COVID-19 pandemic
• Analysts identify the second quarter as the critical test period, with claims from Q1 being paid in April-May, and caution that one-time factors like weather disruptions and weak respiratory season may have artificially lowered Q1 costs

Summary: Easing Medical Costs Benefit Health Insurers, But Uncertainty Remains

U.S. health insurers delivered strong first-quarter results, exceeding analyst expectations after three years of elevated medical costs that drove the S&P managed care index down over 12% since July 2023. Major insurers including UnitedHealth Group, Cigna, Humana, Elevance Health, and Centene reported better-than-expected earnings, marking their strongest performance since the COVID-19 pandemic.

Key Developments:

Medical costs came in below estimates during Q1, with insurers demonstrating improved cost management. The sector had been strained by increased healthcare utilization in Medicare plans and enrollment changes in Medicaid that brought sicker, costlier members into coverage.

Market Implications:

Despite positive results, analysts remain cautious, emphasizing the need for a second consecutive strong quarter before confirming a lasting trend. The second quarter is historically viewed as the critical test period, with claims from Q1 typically processed in April and May.

Concerns and Caveats:

Analysts identified several one-time factors potentially inflating Q1 performance:

• Weak respiratory/flu season
• Weather disruptions delaying care
• Lower first-quarter claims as members haven't met deductibles

However, some analysts argue that fundamental strength exists beyond temporary factors. Oppenheimer's Wiederhorn noted that unsustainable medical cost levels from the past two years may finally be decelerating, while Cantor's analysis suggested core strength rather than artificial benefits.

Outlook:

UBS analyst AJ Rice indicated potential for further positive earnings revisions if cost trends continue stabilizing. UnitedHealth's CFO emphasized the importance of monitoring April and May data, stating that continued Q1 trends could lead to a "very strong year."